Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$3.72
-1.3%
$3.70
$2.68
$66.00
$12.68M2.36104,743 shs54,121 shs
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$0.34
+1.8%
$0.42
$0.29
$3.60
$14.87M1.44284,575 shs372,238 shs
Cue Health Inc. stock logo
HLTH
Cue Health
$0.04
-29.8%
$0.07
$0.04
$0.74
$6.91M1.0913.38 million shs96.00 million shs
Precipio, Inc. stock logo
PRPO
Precipio
$9.57
-1.9%
$6.46
$3.90
$10.74
$14.46M1.129,377 shs10,050 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-1.33%-1.85%-9.27%-30.60%-94.41%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
+1.82%-1.00%-15.55%-66.04%-89.81%
Cue Health Inc. stock logo
HLTH
Cue Health
0.00%0.00%0.00%0.00%-59.44%
Precipio, Inc. stock logo
PRPO
Precipio
-0.89%+20.39%+24.22%-5.67%+57.45%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
1.4947 of 5 stars
3.14.00.00.00.60.00.6
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
3.6028 of 5 stars
3.33.00.04.50.61.70.6
Cue Health Inc. stock logo
HLTH
Cue Health
N/AN/AN/AN/AN/AN/AN/AN/A
Precipio, Inc. stock logo
PRPO
Precipio
1.1943 of 5 stars
0.03.00.00.02.92.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
2.25
Hold$7.0088.17% Upside
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
2.50
Moderate Buy$3.00792.33% Upside
Cue Health Inc. stock logo
HLTH
Cue Health
0.00
N/AN/AN/A
Precipio, Inc. stock logo
PRPO
Precipio
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest HLTH, HBIO, PRPO, and BNGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSpeculative Buy ➝ Speculative Buy$4.50 ➝ $3.00
4/9/2025
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
4/9/2025
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Sector Weight
4/2/2025
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$1.00 ➝ $4.00
3/24/2025
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSpeculative Buy ➝ Speculative Buy$5.50 ➝ $4.50
(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$28.46M0.44N/AN/A$125.85 per share0.03
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$91.40M0.16$0.07 per share5.16$1.71 per share0.20
Cue Health Inc. stock logo
HLTH
Cue Health
$70.94M0.10N/AN/A$1.62 per share0.03
Precipio, Inc. stock logo
PRPO
Precipio
$20.03M0.72N/AN/A$10.16 per share0.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-$232.49M-$138.92N/AN/A-407.34%-154.45%-80.78%8/6/2025 (Estimated)
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$3.41M-$1.32N/AN/A-14.57%-4.64%-2.40%N/A
Cue Health Inc. stock logo
HLTH
Cue Health
-$373.46M-$2.44N/AN/AN/A-526.48%-67.82%-53.79%N/A
Precipio, Inc. stock logo
PRPO
Precipio
-$5.85M-$2.07N/AN/A-17.23%-34.01%-25.27%8/11/2025 (Estimated)

Latest HLTH, HBIO, PRPO, and BNGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-$3.49-$1.15+$2.34-$1.15$6.25 million$6.46 million
5/14/2025Q1 2025
Precipio, Inc. stock logo
PRPO
Precipio
N/A-$0.59N/A-$0.59N/A$4.93 million
3/27/2025Q4 2024
Precipio, Inc. stock logo
PRPO
Precipio
$0.74-$0.23-$0.97-$0.23$8.01 million$5.45 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
N/AN/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
N/AN/AN/AN/AN/A
Cue Health Inc. stock logo
HLTH
Cue Health
N/AN/AN/AN/AN/A
Precipio, Inc. stock logo
PRPO
Precipio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
0.07
1.43
0.99
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
0.52
2.06
0.91
Cue Health Inc. stock logo
HLTH
Cue Health
N/A
2.54
2.22
Precipio, Inc. stock logo
PRPO
Precipio
0.02
0.73
0.60

Institutional Ownership

CompanyInstitutional Ownership
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
11.35%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
80.87%
Cue Health Inc. stock logo
HLTH
Cue Health
45.49%
Precipio, Inc. stock logo
PRPO
Precipio
10.45%

Insider Ownership

CompanyInsider Ownership
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
1.60%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
9.00%
Cue Health Inc. stock logo
HLTH
Cue Health
12.50%
Precipio, Inc. stock logo
PRPO
Precipio
16.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
3003.36 million1.92 millionOptionable
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
49044.21 million39.69 millionOptionable
Cue Health Inc. stock logo
HLTH
Cue Health
726159.09 million139.21 millionOptionable
Precipio, Inc. stock logo
PRPO
Precipio
601.51 million1.29 millionNo Data

Recent News About These Companies

Precipio Announces its Q1-2025 Financial Results
Precipio trading halted, volatility trading pause
Precipio achieves positive adjusted EBITDA, cash flow in Q4

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bionano Genomics stock logo

Bionano Genomics NASDAQ:BNGO

$3.72 -0.05 (-1.33%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$3.80 +0.08 (+2.15%)
As of 05/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Harvard Bioscience stock logo

Harvard Bioscience NASDAQ:HBIO

$0.34 +0.01 (+1.82%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$0.33 -0.01 (-3.03%)
As of 05/23/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Cue Health stock logo

Cue Health NASDAQ:HLTH

Cue Health Inc. operates as a healthcare technology company. It provides the Cue Health platform that offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a range of health and wellness needs. It offers Cue Integrated Care platform comprising hardware, software, and diagnostic components, such as Cue Health Monitoring System consisting of Cue Reader, a portable and reusable reader, Cue Cartridge, a single-use test cartridge, and Cue Wand, a sample collection wand; Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability; Cue Virtual Care Delivery Apps, which include Cue Health App and Cue Enterprise Dashboard; and Cue Ecosystem Integrations and Apps, including integration with electronic medical record system, pharmacies and last-mile delivery, clinician networks, and laboratories. The company also provides COVID-19 testing kits. The company was formerly known as Cue Inc and changed its name to Cue Health Inc. in December 2017. Cue Health Inc. was incorporated in 2010 and is headquartered in San Diego, California.

Precipio stock logo

Precipio NASDAQ:PRPO

$9.56 -0.19 (-1.90%)
Closing price 05/23/2025 03:58 PM Eastern
Extended Trading
$9.68 +0.11 (+1.15%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.